Convalescent plasma therapy: A promising solution for SARS-CoV-2 outbreak

Abstract

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has caused more than 18 million confirmed cases and 700000 deaths worldwide after the outbreak in November 2019 (COVID-19). It has been considered as most pathogenic infection under this category. Till date none of the therapeutics or prophylaxis measures have been claimed by any researcher which could cure the patient suffering from the SARS-CoV-2 infection. There is an urgent need for any alternative and effective way of disease management for COVID-19. However, convalescent plasma therapy (CPT) has gain attention of researchers with significant improvement of patient survival rate. Interestingly, there are numerous examples where CPT has proven its potential upon post-exposure prophylaxis and/or treatment in various diseases including COVID-19. This review summarizes the essential elements related to CPT, its past clinical evidences and application of CPT for the management of SARS-CoV-2 infection during COVID-19. We used the published literatures from PubMed, EMBASE and Medline databases until 31st May 2020.

Point mutation of COVID-19 proteins: A study on noval corona virus (nCov) correlation with MERS and H1N1 viruses and in silico investigation of nCoV proteins for future applications

“…The present report is based on an in silico study of nCoV and associated virus genome sequences analysis to understand the relationship with these respiratory tract infecting viruses. However, the genome sequences of nCoV, SARS-CoV, MERS-CoV was compared with bat-CoV (RaTG13) by Zhou et al where they found similarity 96% with nCoV and 76% with SARS-CoV [6,12]. Additionally, we have compared the all the protein sequences submitted for nCoV on NCBI from all over the world to find the regions where mutation not happened during the spread which is common in viruses.…”